

PO-99

## Aflibercept for the Management of Refractory Macular Edema of Irvine-Gass Syndrome – Case Report

以采視明處理難治的白內障術後黃斑囊樣水腫 – 病例報告

林純如, 陳文祿, 林正明, 田韌太, 何宜豪, 蔡宜佑  
中國醫藥大學附設醫院 眼科部

**Purpose:** A patient with pseudophakic cystoid macular edema (CME) refractory to current standard topical treatment was enrolled. We report the functional and anatomical outcome after subsequent intravitreal aflibercept injections in a patient with CME related to Irvine-Gass syndrome.

**Methods:** Interventional case report.

**Results:** An 83-year-old woman complained of visual disturbances after uneventful cataract surgery for 1 month OS. FA ad OCT confirmed the diagnosis of pseudophakic CME related to Irvine-Gass syndrome. After one posterior subtenon triamcinolone and three intravitreal monthly ranibizumab injections, CME persisted at the 4-month visit. One intravitreal aflibercept injection was tried. The CMT decreased after 1 month. She chose observation; however, the CMT increased at the 2-month visit. So three intravitreal monthly aflibercept injections were given. The CMT subsided at the last follow-up. There were no ocular or systemic complications related to the intravitreal injections.

**Conclusions:** Intravitreal aflibercept appeared to be an effective treatment of refractory CME related to Irvine-Gass syndrome. Recurrent macular edema has been observed after only one aflibercept injection but was subsided after 3 subsequent monthly injections. Prospective controlled studies are warranted to compare the long-term safety and efficacy between intravitreal aflibercept and other treatment options in cases of Irvine-Gass syndrome.

**Purpose:** We re

rhegmatogenous  
and choroidal  
melanoma.

**Methods:** Interv

**Results:** A 59-

disturbances a  
month OS. Fu

lower RD an  
quadrant. OC

fluid. B scan  
internal refle

of mixed hy  
lesion and c  
late phase.

enhancing  
18F-fluoro  
uptake valu

show any s  
evidence o

also soug  
vitrectom

on the sl  
Specimen

postoper

Patholog

photo d  
break w

neither  
fluid.

**Concl**

hemor  
differ  
CT an  
morph

is nec